Pharmaceutical CAS 159351-69-6 Everolimus 99% Purity Everolimus Raw Material Powder Everolimus

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: Dsung-Everolimus
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Everolimus
• Name: Everolimus Powder
• Appearance: White or off-White Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical Intermediates
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 159351-69-6
• Mf: C53h83no14
• MW: 958.24
• Density: 1.18
• Boiling Point: 998.7 C at 760 Mmhg
• Refractive Index: 1.548
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 500kg/Month

Product Description

Pharmaceutical CAS 159351-69-6 Everolimus 99% Purity Everolimus Raw Material Powder Everolimus

 

Product Description

Product Details

Product Name	Everolimus
CAS No.	159351-69-6
MF	C53H83NO14
MW	958.24
Appearance and shape	White or off-white powder

Everolimus is used to treat advanced (late-stage) cancers or noncancerous tumors, such as kidney and breast cancer, subependymal giant cell astrocytoma (SEGA, a brain tumor), renal angiomyolipoma (kidney tumor), and partial-onset seizures (epilepsy) with tuberous sclerosis complex (TSC), and neuroendocrine tumors of the pancreas, stomach or bowels, and lungs.  It is used for patients who have already received other medicines that did not work well or those who will not be treated with surgery.
Everolimus works by interfering with the growth of cancer cells, which are eventually destroyed by the body.  Since the growth of normal body cells may also be affected, other unwanted effects will also occur.  It belongs to the group of medicines known as antineoplastics (cancer medicines).
Everolimus is also used together with other medicines to lower the body's natural immunity in patients who receive kidney or liver transplants.  When a patient receives an organ transplant, the body's white blood cells try to get rid of (reject) the transplanted organ.  Everolimus works to suppress the immune system and prevents the white blood cells from getting rid of the transplanted organ.

Application & Function

1.  Macrolide immunosuppressant;  derivative of Rapamycin.  Inhibits cytokine-mediated lymphocyte proliferation
2.  Everolimus (IX) (SDZ-RAD), was developed by Novartis as an immunosuppressant to be used in conjunction with cyclosporin in transplantation allograft rejection and was recently approved in the US in 2003.  Another natural product that had been approved for use in transplantation is rapamycin (sirolimus) as an inejectable agent.  In an attempt to develop an orally bioavailable immunosuppressant agent, many companies attempted modification of rapamycin itself.
3.  Everolimus Macrolide immunosuppressant;  Everolimus is a derivative of Rapamycin.  Everolimus inhibits cytokine-mediated lymphocyte proliferation.
4.  Everolimus is a semi-synthetic macrocyclic lactone prepared from rapamycin by selective alkylation of the 42-hydroxy group with a silyl-protected hydroxyethyl triflate moiety, followed by addition of an ethylhydroxy moiety to provide greater stability and bioavailability.  Like all tacrolimus analogues, everolimus binds to receptor protein, FKBP12.  The complex then binds to mTOR preventing it from interacting with target proteins.  Everolimus is extensively cited in the literature with over 2,000 citations.

Specification